2oow: Difference between revisions
New page: left|200px<br /> <applet load="2oow" size="450" color="white" frame="true" align="right" spinBox="true" caption="2oow, resolution 1.750Å" /> '''MIF Bound to a Flu... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2oow. | [[Image:2oow.jpg|left|200px]]<br /><applet load="2oow" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="2oow" size=" | |||
caption="2oow, resolution 1.750Å" /> | caption="2oow, resolution 1.750Å" /> | ||
'''MIF Bound to a Fluorinated OXIM Derivative'''<br /> | '''MIF Bound to a Fluorinated OXIM Derivative'''<br /> | ||
| Line 6: | Line 5: | ||
==Overview== | ==Overview== | ||
Pharmacophores are chemical scaffolds upon which changes in chemical, moieties (R-groups) at specific sites are made to identify a combination, of R-groups that increases the therapeutic potency of a small molecule, inhibitor while minimizing adverse effects. We developed a pharmacophore, based on a carbonyloxime (OXIM) scaffold for macrophage migration, inhibitory factor (MIF), a protein involved in the pathology of sepsis, to, validate that inhibition of a catalytic site could produce therapeutic, benefits. We studied the crystal structures of MIF:OXIM-based inhibitors, and found two opposite orientations for binding to the active site that, were dependent on the chemical structures of an R-group. One orientation, was completely unexpected based on previous studies with, hydroxyphenylpyruvate and, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester, (ISO-1). We further confirmed that the unexpected binding mode targets MIF, in cellular studies by showing that one compound, OXIM-11, abolished the, counter-regulatory activity of MIF on anti-inflammatory glucocorticoid, action. OXIM-11 treatment of mice, initiated 24h after the onset of cecal, ligation and puncture-induced sepsis, significantly improved survival, compared to vehicle-treated controls confirming that inhibition of the MIF, catalytic site could produce therapeutic effects. The crystal structures, of the MIF-inhibitor complexes provide insight for further structure-based, drug design efforts. | Pharmacophores are chemical scaffolds upon which changes in chemical, moieties (R-groups) at specific sites are made to identify a combination, of R-groups that increases the therapeutic potency of a small molecule, inhibitor while minimizing adverse effects. We developed a pharmacophore, based on a carbonyloxime (OXIM) scaffold for macrophage migration, inhibitory factor (MIF), a protein involved in the pathology of sepsis, to, validate that inhibition of a catalytic site could produce therapeutic, benefits. We studied the crystal structures of MIF:OXIM-based inhibitors, and found two opposite orientations for binding to the active site that, were dependent on the chemical structures of an R-group. One orientation, was completely unexpected based on previous studies with, hydroxyphenylpyruvate and, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester, (ISO-1). We further confirmed that the unexpected binding mode targets MIF, in cellular studies by showing that one compound, OXIM-11, abolished the, counter-regulatory activity of MIF on anti-inflammatory glucocorticoid, action. OXIM-11 treatment of mice, initiated 24h after the onset of cecal, ligation and puncture-induced sepsis, significantly improved survival, compared to vehicle-treated controls confirming that inhibition of the MIF, catalytic site could produce therapeutic effects. The crystal structures, of the MIF-inhibitor complexes provide insight for further structure-based, drug design efforts. | ||
==About this Structure== | ==About this Structure== | ||
2OOW is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with SO4, OX4, GOL and IPA as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phenylpyruvate_tautomerase Phenylpyruvate tautomerase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=5.3.2.1 5.3.2.1] Full crystallographic information is available from [http:// | 2OOW is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=SO4:'>SO4</scene>, <scene name='pdbligand=OX4:'>OX4</scene>, <scene name='pdbligand=GOL:'>GOL</scene> and <scene name='pdbligand=IPA:'>IPA</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phenylpyruvate_tautomerase Phenylpyruvate tautomerase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=5.3.2.1 5.3.2.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2OOW OCA]. | ||
==Reference== | ==Reference== | ||
| Line 27: | Line 23: | ||
[[Category: alternative ligand-binding modes]] | [[Category: alternative ligand-binding modes]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 15:01:20 2008'' | ||
Revision as of 16:01, 23 January 2008
|
MIF Bound to a Fluorinated OXIM Derivative
OverviewOverview
Pharmacophores are chemical scaffolds upon which changes in chemical, moieties (R-groups) at specific sites are made to identify a combination, of R-groups that increases the therapeutic potency of a small molecule, inhibitor while minimizing adverse effects. We developed a pharmacophore, based on a carbonyloxime (OXIM) scaffold for macrophage migration, inhibitory factor (MIF), a protein involved in the pathology of sepsis, to, validate that inhibition of a catalytic site could produce therapeutic, benefits. We studied the crystal structures of MIF:OXIM-based inhibitors, and found two opposite orientations for binding to the active site that, were dependent on the chemical structures of an R-group. One orientation, was completely unexpected based on previous studies with, hydroxyphenylpyruvate and, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester, (ISO-1). We further confirmed that the unexpected binding mode targets MIF, in cellular studies by showing that one compound, OXIM-11, abolished the, counter-regulatory activity of MIF on anti-inflammatory glucocorticoid, action. OXIM-11 treatment of mice, initiated 24h after the onset of cecal, ligation and puncture-induced sepsis, significantly improved survival, compared to vehicle-treated controls confirming that inhibition of the MIF, catalytic site could produce therapeutic effects. The crystal structures, of the MIF-inhibitor complexes provide insight for further structure-based, drug design efforts.
About this StructureAbout this Structure
2OOW is a Single protein structure of sequence from Homo sapiens with , , and as ligands. Active as Phenylpyruvate tautomerase, with EC number 5.3.2.1 Full crystallographic information is available from OCA.
ReferenceReference
Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of MIF., Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B, Pavlov VA, Miller EJ, Lolis E, Al-Abed Y, J Biol Chem. 2007 May 25;. PMID:17526494
Page seeded by OCA on Wed Jan 23 15:01:20 2008